PANDION THERAPEUTICS INC has a total of 37 patent applications. Its first patent ever was published in 2018. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Brazil. Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are GENMAB BV, NOVETIDE LTD and BOLDER BIOTECHNOLOGY INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 10 | |
#2 | WIPO (World Intellectual Property Organization) | 7 | |
#3 | Brazil | 3 | |
#4 | Canada | 3 | |
#5 | China | 3 | |
#6 | EPO (European Patent Office) | 3 | |
#7 | Israel | 3 | |
#8 | Republic of Korea | 3 | |
#9 | Singapore | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Enzymes |
# | Name | Total Patents |
---|---|---|
#1 | Viney Joanne L | 30 |
#2 | Higginson-Scott Nathan | 28 |
#3 | Otipoby Kevin Lewis | 19 |
#4 | Visweswaraiah Jyothsna | 17 |
#5 | Sampson Erik Robert | 15 |
#6 | Crane Alan | 5 |
#7 | Benson Micah | 5 |
#8 | Glanville Jacob | 3 |
#9 | Alioto Salvatore | 3 |
#10 | Joanne L Viney | 3 |
Publication | Filing date | Title |
---|---|---|
WO2021034890A1 | Targeted immunotolerance with a pd-1 agonist | |
US2020392228A1 | MAdCAM TARGETED IMMUNOTOLERANCE | |
WO2020061142A1 | Targeted immunotolerance | |
BR112020011343A2 | il-2 muteins and their uses | |
WO2019112852A1 | Targeted immunotolerance | |
US2019321446A1 | IL-2 muteins and uses thereof | |
US10174092B1 | IL-2 muteins | |
CN111010866A | Targeted immune tolerance | |
BR112019018915A2 | targeted immunotolerance |